HiRO and Differentia Biotech Sign MOU for AI Clinical Trial Simulation
HiRO and Differentia Biotech signed a Memorandum of Understanding to collaborate on AI powered clinical trial simulation, the companies announced in a press release. The agreement was formalized at HiRO's office and covers joint work on simulation models and related commercial offerings for biopharmaceutical sponsors.
The collaboration will combine HiRO's clinical operations, data science, and real world data work with Differentia Biotech's digital twin, modeling, and simulation platforms. The companies said the models will focus on trial design, patient selection, subject number planning, and earlier sponsor decision making.
HiRO said the work will apply across complex areas including oncology, rare disease, cell and gene therapy, and radiopharmaceuticals. The companies said they expect to share more details on specific initiatives as the partnership progresses.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 12 Aignostics Opens Early Access to PathoSearch Sep 11 Ultima Genomics and NVIDIA Collaborate on Pangenome Sequencing Analysis Sep 11 UrgentIQ Raises $15 Million for AI Clinical Workflows Sep 11 Penguin Ai Launches Revenue Cycle AI Platform Sep 11 MegazoneCloud Builds Quality Assurance AI Agent for Hanmi PharmaceuticalLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
ARPA-H Awards UpDoc Up to $9.2 Million for Clinical AI
UT Medical and TransformativeMed Build Agentic AI Discharge Planning Tool
Probably Genetic Gets Up to $10M ARPA-H Contract for Rare Disease AI
Mednet Launches TrialMatch for Cancer Clinical Trial Discovery
Mistral AI and Cloudera Partner on Sovereign Enterprise AI
Daily AI Brief: the AI news that matters, in your inbox.